Aňa Lluch

26.1k total citations · 5 hit papers
306 papers, 14.7k citations indexed

About

Aňa Lluch is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Aňa Lluch has authored 306 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Oncology, 148 papers in Cancer Research and 62 papers in Molecular Biology. Recurrent topics in Aňa Lluch's work include Breast Cancer Treatment Studies (102 papers), Cancer Treatment and Pharmacology (99 papers) and HER2/EGFR in Cancer Research (91 papers). Aňa Lluch is often cited by papers focused on Breast Cancer Treatment Studies (102 papers), Cancer Treatment and Pharmacology (99 papers) and HER2/EGFR in Cancer Research (91 papers). Aňa Lluch collaborates with scholars based in Spain, United States and Italy. Aňa Lluch's co-authors include Pîlar Eroles, Luca Gianni, Pinuccia Valagussa, Semiglazov Vf, José Alejandro Pérez Fidalgo, Ana Bosch, Joan Albanell, J Garcı́a-Conde, José Baselga and Juan de la Haba-Rodríguez and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Aňa Lluch

294 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

2011 1.5k citations Aňa Lluch et al. profile →
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005 1.2k citations Aňa Lluch et al. profile →
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Aňa Lluch et al. profile →
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

2016 555 citations Aňa Lluch et al. profile →
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017 479 citations Henry Gómez, Aňa Lluch et al. profile →

Peers

Countries citing papers authored by Aňa Lluch

Since Specialization

Citations

This map shows the geographic impact of Aňa Lluch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aňa Lluch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aňa Lluch more than expected).

Fields of papers citing papers by Aňa Lluch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aňa Lluch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aňa Lluch. The network helps show where Aňa Lluch may publish in the future.

Co-authorship network of co-authors of Aňa Lluch

This figure shows the co-authorship network connecting the top 25 collaborators of Aňa Lluch. A scholar is included among the top collaborators of Aňa Lluch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aňa Lluch. Aňa Lluch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer 2024 ·Cell Death Discovery ·(unknown), Iris Garrido‐Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernándo, María Teresa Martínez, Federico Rojo, Begoña Bermejo, (unknown), Juan Antonio Carbonell‐Asins, (unknown), Aňa Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pîlar Eroles	5
2	High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer 2023 ·International Journal of Molecular Sciences ·(unknown), Eduardo Tormo, Iris Garrido‐Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz‐Gúrpide, Octavio Burgués, Cristina Hernándo, Begoña Bermejo, María Teresa Martínez, Aňa Lluch, Juan Miguel Cejalvo, Pîlar Eroles	4
3	Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective 2021 ·International Journal of Molecular Sciences ·Cristina Hernándo, (unknown), (unknown), (unknown), María Teresa Martínez, Pîlar Eroles, Iris Garrido‐Cano, Anna Adam‐Artigues, Aňa Lluch, Begoña Bermejo, Juan Miguel Cejalvo	78
4	Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool 2021 ·ACS Sensors ·Iris Garrido‐Cano, (unknown), Sara Santiago‐Felipe, (unknown), (unknown), Begoña Bermejo, Aňa Lluch, Juan Miguel Cejalvo, Pîlar Eroles, Ramón Martínez‐Máñez	13
5	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer 2021 ·Cancers ·Anna Adam‐Artigues, Iris Garrido‐Cano, Juan Antonio Carbonell‐Asins, Ana Lameirinhas, (unknown), (unknown), María Teresa Martínez, Cristina Hernándo, Vera Constâncio, Octavio Burgués, Begoña Bermejo, Rui Henrique, Aňa Lluch, Cármen Jerónimo, Pîlar Eroles, Juan Miguel Cejalvo	20
6	Fertility and breast cancer: A literature review of counseling, preservation options and outcomes 2021 ·Critical Reviews in Oncology/Hematology ·(unknown), Raimondo Di Liello, Begoña Bermejo, Cristina Hernándo, (unknown), Isabel Chirivella, Aňa Lluch, Juan Miguel Cejalvo, María Teresa Martínez	15
7	HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women 2020 ·Cancers ·Sara S. Oltra, Juan Miguel Cejalvo, Eduardo Tormo, (unknown), Ana Ferrer, (unknown), Begoña Bermejo, Cristina Hernándo, Isabel Chirivella, Elisa Alonso, Octavio Burgués, María Peña-Chilet, Pîlar Eroles, Aňa Lluch, Gloría Ribas, María Teresa Martínez	14
8	Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer 2020 ·International Journal of Molecular Sciences ·Iris Garrido‐Cano, Vera Constâncio, Anna Adam‐Artigues, Ana Lameirinhas, (unknown), (unknown), María Teresa Martínez, Cristina Hernándo, Begoña Bermejo, Aňa Lluch, Paula Lopes, Rui Henrique, Cármen Jerónimo, Juan Miguel Cejalvo, Pîlar Eroles	27
9	The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors 2019 ·Scientific Reports ·Eduardo Tormo, Sandra Ballester, Anna Adam‐Artigues, Octavio Burgués, Elisa Alonso, Begoña Bermejo, Sílvia Menéndez, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Rovira, Joan Albanell, Federico Rojo, Aňa Lluch, Pîlar Eroles	71
10	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer 2016 ·Molecular Cancer Therapeutics ·Raúl Rincón, Sandra Zazo, Cristina Chamizo, Rebeca Manso, Paula Gónzález-Alonso, Ester Martı́n-Aparicio, Ion Cristóbal, Carmen Cañadas, Rosario Perona, Aňa Lluch, Pîlar Eroles, Jesús García‐Foncillas, Joan Albanell, Ana Rovira, Juan Madoz‐Gúrpide, Federico Rojo	12
11	Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis 2014 ·Cancer Research ·Jelena Stanisavljević, Jordina Loubat‐Casanovas, Mercedes Herrera, Tomás Luque, Raúl Peña, Aňa Lluch, Joan Albanell, Félix Bonilla, Ana Rovira, Cristina Peña, Daniel Navajas, Federico Rojo, Antonio Garcı́a de Herreros, Josep Baulida	98
12	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Funda Meric‐Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, José Alejandro Pérez Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pîlar Eroles, Juan Antonio Barrera, Octavio Burgués, Aňa Lluch, Xiaofeng Zheng, Ayşegül Şahin, Philip J. Stephens, Gordon B. Mills, Maureen Cronin, Ana M. González-Angulo	68
13	Genetic variants in PARP1 (rs3219090) and IRF4(rs12203592) genes associated with melanoma susceptibility in a Spanish population 2013 ·BMC Cancer ·María Peña-Chilet, (unknown), Maider Ibarrola‐Villava, Conrado Martínez‐Cadenas, Manuel Martín‐González, Cristina Gómez‐Fernández, Matías Mayor, (unknown), Aňa Lluch, Gloría Ribas	30
14	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer 2010 ·Clinical Cancer Research ·Adel Tabchy, Vicente Valero, Tatiana Vidaurre, Aňa Lluch, Henry Gómez, Miguel Martín, Yuan Qi, Luis Javier Barajas-Figueroa, Eduardo Souchon, Charles Coutant, Franco D. Doimi, Nuhad K. Ibrahim, Yun Gong, Gabriel N. Hortobágyi, Kenneth R. Hess, W. Fraser Symmans, Lajos Pusztai	160
15	Clinical approach to fertility making-decisions in breast cancer patients 2010 ·Complutensian Scientific Journals (Complutense University of Madrid) ·(unknown), Aňa Lluch, Begoña Bermejo	2
16	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer 2009 ·Clinical Cancer Research ·Roshan Agarwal, (unknown), Simen Myhre, Mark Carey, Ju‐Seog Lee, Jens Overgaard, Jan Alsner, Katherine Stemke‐Hale, Aňa Lluch, Richard M. Neve, Wen Lin Kuo, Thérese Sørlie, Ayşegül A. Şahin, Vicente Valero, Khandan Keyomarsi, Joe W. Gray, Anne‐Lise Børresen‐Dale, Gordon B. Mills, Bryan T. Hennessy	111
17	Estudio sobre la derivación de pacientes oncológicos a la unidad de psico-oncología según criterio médico 2009 ·Complutensian Scientific Journals (Complutense University of Madrid) ·Pilar Moreno, (unknown), Aňa Lluch	2
18	Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer 2007 ·Cancer Research ·Joan Climent, (unknown), Jane Fridlyand, José Palacios, Reiner Siebert, Donna G. Albertson, Joe W. Gray, Daniel Pinkel, Aňa Lluch, José A. Martínez-Climent	67
19	Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. 2002 ·PubMed ·Joan Climent, José A. Martínez-Climent, David Blesa, María J. García‐Barchino, Rosana Sáez, Dolors Sánchez-Izquierdo, (unknown), Aňa Lluch, J Garcı́a-Conde	32
20	NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. 2002 ·PubMed ·Miguel Ángel Molina‐Vila, Rosana Sáez, Elizabeth E. Ramsey, María J. García‐Barchino, Federico Rojo, A. Evans, Joan Albanell, Edward J. Keenan, Aňa Lluch, J Garcı́a-Conde, José Baselga, Gail M. Clinton	177

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact